	í	•	IPE	/	Docket Number (Optional) 5771-PI-01-		Application Number	r 759,777				
•	INFO	DRMATION DISCLOSURE	·/	Scros	Applicant(s) MARIA I. GONZAI			,				
(Use several sheets if necessary			( FEB 1 6 2	EGE MO	Filing Date Grou		Group Art Unit	up Art Unit				
-			B	<u> </u>	JANUARY 12,	, 2001	·					
PATENT DOCUMENTS												
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO				
			· · · · · · · · · · · · · · · · · · ·									
				ļ			A A					
							\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	<u>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</u>				
						I Po	March I	1/6	<b>&gt;</b>			
	<u>-</u>						ENTER	2007	)			
							10%	12000				
					- "							
								<u>, , , , , , , , , , , , , , , , , , , </u>				
							1	<del></del>				
									T			
		<u> </u>										
		T	<u>r</u>	FOREIGN	N PATENT DOCUMENTS	· 	T	1				
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	NO NO			
mo	ù	98/07718	02/26/1998	wo				1				
									÷.			
								<del></del>				
	<u> </u>											
			J	OTHER F	OOCUMENTS (Includin	e Author. Title 1	ate, Pertinent Pa	ges, Etc.)	l			
-		Berman J.R. et al. Clini physiologic sexual respo	cal evaluation of		,				ıd			
$M_{\lambda}$	2	Dutta A.S. (1993) in Sm							:			
EXAMINER .		<i>i</i>	Battey J. et al. (1991), Trends Neurosci. 14: 524									
			Lebacq-Verheyden A. et al. (1990) Handbook of Experimental Pharmacology 95 (Part II): 71  Pharmaceutical salts" by Berge S.M. et al. (1997) J. Pharm. Sci. 66: 1-19									
		WILL	DATE CONSIDERED 0//1///2									
		ial if citation considered, whether o			e with MPEP Section 609;	Draw line throug	th citation if not i	n conforma	nce and not			
considered.	Includ	de copy of this form with next com	nunication to appl	icant.				-	7.			

		IPE I	Docket Number (Optional)	Application Number				
TAUCA	SDM A	TION DISCLOSURE OTTATION	5771-P1-01-BD	09/759,777				
INFO		TION DISCLOSURE OTTATION  (Use several sheets if necessary)  FEB 1 6 2001	Applicant(s) MARIA I. GONZALEZ, ET AL.					
			Filing Date JANUARY 12, 2001	Group Art Unit				
*EXAMINER	$\overline{}$	1						
INITIAL			e, Date, Pertinent Pages, Etc.)					
M	(	Æhe Merck Manual, 17th edition, 1999						
	/	-Woodruff G.N. et al (1996) in: Neuropeptides: Basic and Clinical Advances, eds J.N. Crawley and - S. McLean (The New York Academy of Sciences, New York) p. 223						
	- A	York Academy of Sciences, New York) p. 223  Ladenheim et al., 1992, Br. Res. 593: 168-178  Toney et al., Br. Res. 1992, 598: 279-285  Plamondon H. et al. (1996) Soc. Neurosci. 22: Abstract 181.13  Hurel S.J. et al. (Lancet (1996) 348: 1243)  Spurzem J.R. et al. (1997) Am. J. Respir. Cell. Mol. Biol. 16: 209-211  Wang D. et al. (1996) Am. J. Respir. Cell. Mol. Biol. 14: 409-416  Spindel E.R., Ibidem 14: 407-408  Cutz F. et al. (Pediatrics (1996) 98: 668-72						
		Toney et al., Br. Res. 1992, 598: 279-285	λ.	2. CA				
	_	Plamondon H. et al. (1996) Soc. Neurosci. 22: Abstract 181.13						
	<i>_</i>	Hurel S.J. et al. (Lancet (1996) 348: 1243)						
		Spurzem J.R. et al. (1997) Am. J. Respir. Cell. Mol	. Biol . 16: 209-211	Ep. 00,				
		Wang D et al. (1996) Am. J. Respir. Cell. Mol. Bi	ol. 14: 409-416	600				
		Spindel E.R., Ibidem 14: 407-408		~ <del>~</del>				
		Gutz E. et al. (Pediatrics (1996) 98: 668-72	·					
	-	The Merck Index, 12th edition, 1996, p. MISC-10						
	- /	The Merck Index, 12th edition, 1996, page MISC-93						
	r	Safavy A. et al. (1993) Bioconj. Chem. 4: 194-8						
		Safavy A. et al. in Cancer (1997) 80 (Suppl): 2354-9						
	1	Aprikian A.G. et al.(1996) J. Mol. Endocrinol-16: 297-306						
	•	Hoosein N.M., (1993) Cancer Bull. 45:436-441						
	1	Hajri A. et al.(1996) Pancreas 12: 25-35						
	1	Wang Q.J. et al. Int. J. Cancer (1996) 68: 528-34						
	/	Medenica R. et al. (1997) Cell mol. Biol. 43: 9-27						
	1	McColl K.E. et al. (1995) Aliment. Pharmacol. Ther. 9: 341-7						
		Hampton L. et al, Proc. Natl.Acad. Sci. USA, 95: 3188-92, 1998						
	1	Michelot J.M. et al. (1991) in J. Nucl. Med. 32: 1573-80.						
	/	Chun-Cheung (1997) Pharmaproject Magazine November: 24-26						
		M.C. Pritchard et al. (1997) in 9th RSC-Sci Medic	inal Chemistry Symposium, Abstract	i.				
	• /	Eden et al., (1996) Int-J-Pept-Protein-Res, 48(6): 522-31						
	/	Aṣhwood et al., (1998) Bioorganic and Medicinal Chemistry letters, 8: 2589-2594						
	4	PD-168368, Pharmaproject CDv2.0 Copyright 1997 PJB Publications Ltd, Richmond, Surrey, UK.						
	<i>\infty</i>	Nagy et al., (1997) PNAS, 94:652-656.						
\	1	Rogers et al., (1997) Cancer supplement, 80: 12, 24	<b>1</b> 19-2424.					
/nn		Abrahamsson (1996) The Prostate Supplement, 6:3-8.						
Moody and Jensen, (1998) Drugs of the future, 23: 1305-1315.								
		Anastasi A. et al., Experientia, 1971; 27: 166						
DATE CONSIDERED  0//14/82								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and ot considered. Include copy of this form with next communication to applicant.								

×

ri · ·						
• • •	~ PE	Docket Number (Optional) 5771-P1-01-BD	Application Number 09/759,777			
INFO	ORMATION DISCLOSURE CITATION	Applicant(s)				
	(Use several sheets if necessary)	MARIA I. GONZALEZ, ET A				
	(Use several sheets if necessary)	Dling Date JANUARY 12, 2001	Group Art Unit			
*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author Party)	e, Date, Pertinent Pages, Etc.)				
MITAL	Ladenheim E.E et al, Brain Res., 1990; 537: 233-24	0				
MM	Brown M., et al., Life. Sci., 1978; 23: 2721					
ادرمها	Battey J., et al., TINS, 1991;14:524					
	Spruijt B.M. et al. Behavioral Brain Research, 198	6, 20: 19-25				
M	Miceli M.O. and Malsbury C.W., Behavioral Neuroscience, 1985, 99: 1192-1207  Van Wimersma Greidanus TJ. B. et al. Peptides, 1985, 6: 369-372  Vanderspek et al., Cancer Research, (1997), 57:290-294					
10	Van Wimersma Greidanus TJ. B. et al. Peptides, 1	985, 6: 369-372	(\$C <sub>4</sub>			
	Vanderspek et al., Cancer Research, (1997), 57:290	)-294	75 050 5/10			
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			CHO CI			
1			CENTER 2502			
7			1600			
/			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			
			-40			
		/				
	•					
		/				
			·			
	1/1	Γ				
EXAMINER DATE CONSIDERED 27						
01/17/						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and ot considered. Include copy of this form with next communication to applicant.						